NCT03772457

Predictive Value of Infarction Volume on Hemorrhagic Transformation in Ischemic Stroke/TIA With Non-valve Atrial Fibrillation(NVAF) Patients Using Rivaroxaban

To Explore the Predictive Value of Infarction Volume on Hemorrhagic Transformation in Newly Diagnosed Ischemic Stroke/TIA With Non-valve Atrial Fibrillation(NVAF) Patients Using Rivaroxaban

• Status: Unknown
• Phase: —
• Study type: Observational
• Enrollment: 400 (estimated)
• Sponsor: Second Affiliated Hospital, School of Medicine, Zhejiang University · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

This study was aimed at patients with newly diagnosed stroke / TIA associated with nonvalvular atrial fibrillation. We will observe the effect of early using rivaroxaban anticoagulation on hemorrhagic transformation, and explore the predictive value of multi-mode MRI infarct volume / MMP-9 on hemorrhagic transformation after anticoagulation therapy.

Conditions

• Cerebrovascular Stroke
• Intracranial Hemorrhages
• Anticoagulant
• Matrix Metalloproteinases

Interventions

Type	Name	Description
DRUG	Rivaroxaban	new oral anticoagulant molecules which is the selective factor Xa inhibitor

Timeline

• Start date: 2019-01-18
• Primary completion: 2023-12-31
• Completion: 2024-12-31
• First posted: 2018-12-11
• Last updated: 2023-04-18

Locations

1 site across 1 country: China

Regulatory

• FDA-regulated drug study